All stock lists
Fate Therapeutics Inc (NASDAQ:FATE)
US · Delayed Price · Currency is USD
2.11+0.02 (+0.96%)
Insider Score
––Not scored
FATE Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
FATE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 2.08 M | 1.30 M | 1.37 M | 1.74 M | 1.91 M | 1.63 M |
| Revenue Growth (YoY) | 9.18 % | -20.26 % | -26.40 % | -43.36 % | -71.84 % | -15.38 % |
| Cost of Revenue | 0.00 | 2.92 M | 0.00 | 25.84 M | 3.82 M | 29.14 M |
| Gross Profit | 2.08 M | -1.62 M | 1.37 M | -24.10 M | -1.91 M | -27.51 M |
| SG&A Expense | 8.83 M | 9.60 M | 10.66 M | 10.64 M | 11.45 M | 13.77 M |
| R&D Expense | 24.39 M | 21.79 M | 25.43 M | 25.84 M | 27.43 M | 29.14 M |
| Operating Expenses | 33.22 M | 31.38 M | 36.09 M | 10.64 M | 35.05 M | 13.77 M |
| Operating Income | -31.13 M | -33.00 M | -34.72 M | -34.73 M | -36.97 M | -41.28 M |
| Pretax Income | -30.16 M | -31.21 M | -32.37 M | -32.25 M | -34.07 M | -37.62 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -30.16 M | -31.21 M | -32.37 M | -32.25 M | -34.07 M | -37.62 M |
| EPS (Basic) | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 |
| EPS (Diluted) | -0.25 | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 |
| Shares Outstanding | 120.40 M | 120.03 M | 118.79 M | 119.00 M | 118.53 M | 118.38 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.